Pharmaceutical

Filter

Current filters:

None

Popular Filters

1 to 25 of 7078 results

Oriola-KD considering selling Russian business

21-10-2014

Finland’s Oriola-KD, a leading pharmaceutical retail and wholesale companies operating in Northern…

Mergers & AcquisitionsOriola-KDPharmaceuticalRussia

Ashland Specialty Ingredients opens new pharma center in Wilmington, Delaware

Ashland Specialty Ingredients opens new pharma center in Wilmington, Delaware

21-10-2014

Ashland Specialty Ingredients, the commercial unit of Ashland Inc, has opened a new pharma center in…

AshlandAshland IncPharmaceuticalProductionUSA

FDA panel unanimously backs Novartis’ secukinumab for moderate-to-severe plaque psoriasis

FDA panel unanimously backs Novartis’ secukinumab for moderate-to-severe plaque psoriasis

21-10-2014

The Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) to the US Food and Drug Administration…

DermatologicalsNovartisPharmaceuticalRegulationsecukinumabUSA

FDA fast-tracks Taiho Oncology’s TAS-102 for colorectal cancer

FDA fast-tracks Taiho Oncology’s TAS-102 for colorectal cancer

20-10-2014

The US Food and Drug Administration has granted Fast Track designation for TAS-102 (trifluridine and…

OncologyOtsukaPharmaceuticalRegulationTaiho OncologyTAS-102USA

FDA accepts Eisai's supplemental New Drug Application for Fycompa in tonic-clonic seizures

FDA accepts Eisai's supplemental New Drug Application for Fycompa in tonic-clonic seizures

20-10-2014

Japanese drug major Eisai has had a supplemental New Drug Application for its in-house-discovered AMPA…

CNS DiseasesEisaiFycompaJapanPharmaceuticalRegulation

Pharmacyclics files Imbruvica sNDA for Waldenstrom’s macroglobulinemia

20-10-2014

US drugmaker Pharmacyclics has submitted a supplemental New Drug Application to the US Food and Drug…

ImbruvicaJanssen BiotechJohnson & JohnsonOncologyPharmaceuticalPharmacyclicsRegulationUSA

Grünenthal Group appoints Sascha Becker as group chief financial officer

Grünenthal Group appoints Sascha Becker as group chief financial officer

20-10-2014

German pharma company Grünenthal Group has appointed Sascha Becker as group chief financial officer,…

BoardroomGermanyGrunenthalMerck SeronoPharmaceutical

Forendo licenses fispemifene to Apricus in USA

20-10-2014

Finland-based Forendo Pharma, a Swedish firm Karolinska Development portfolio company, has entered into…

Apricus BiosciencesfispemifeneForendo PharmaGenito-urinaryKarolinska DevelopmentLicensingMen's HealthPharmaceuticalUSA

New report: The myth of high Danish medicine prices

20-10-2014

The price-cap agreements between Lif, the Danish pharmaceutical industry group, and the government help…

DenmarkGenericsPharmaceuticalPricing

Physicians in South Korea and Taiwan expect good uptake of SGLT-2 inhibitors

Physicians in South Korea and Taiwan expect good uptake of SGLT-2 inhibitors

20-10-2014

Prescribers are enthusiastic about the emergence of SGLT2-2 inhibitors for type 2 diabetes, but payers…

AbasriaAsia-PacificDiabetesLantusPharmaceuticalResearch

Shire interim chief financial officer James Bowling to step down after Q1 2015

Shire interim chief financial officer James Bowling to step down after Q1 2015

20-10-2014

James Bowling, interim chief financial officer of Ireland-headquartered drugmaker Shire, has stepped…

BoardroomJames BowlingPharmaceuticalShireUK

Clanotech granted orphan drug designation by EMA for post-glaucoma surgery drug CLT-28643

Clanotech granted orphan drug designation by EMA for post-glaucoma surgery drug CLT-28643

20-10-2014

Swedish ophthalmic specialist Clanotech, which is 80% owned by Karolinska Development, has received orphan…

ClanotechCLT-28643Karolinska DevelopmentOphthalmicsPharmaceuticalRegulationSweden

Viagra found to have potential as heart disease treatment

20-10-2014

Blockbuster erectile dysfunction drug Viagra (sildenafil) could be used as a safe treatment for heart…

Cardio-vascularPfizerPharmaceuticalResearchsildenafilViagra

Scientists say USA’s national Alzheimer's plan milestones must be strengthened to meet goal by 2025

20-10-2014

The US government has initiated a major effort to prevent and effectively treat Alzheimer's disease by…

FinancialNeurologicalPharmaceuticalResearchUSA

US FDA backs abuse deterrent labeling for Pfizer’s Embeda ER

19-10-2014

The US Food and Drug Administration has approved an updated label for pharma giant Pfizer’s Embeda…

AvinzaEmbedaNeurologicalPfizerPharmaceuticalRegulationUSA

Horizon Pharma buys US rights to Nuvo’s Pennsaid for $45 million

19-10-2014

Canadian specialty drugmaker Nuvo Research says it has completed the sale of its osteoarthritis pain…

Anti-Arthritics/RheumaticsHorizon PharmaLicensingMallinckrodtNuvo ResearchPennsaidPharmaceuticalUSA

Indian government takes action on country’s growing mental health problems

18-10-2014

Stigma, ignorance and a severe lack of doctors in India have long marred mental health care projects…

Human InterestIndiaNeurologicalPharmaceutical

GSK Ebola vaccine “too late” for current Ebola outbreak; more on Ebola

17-10-2014

UK pharma giant GlaxoSmithKline says any Ebola vaccine it produces will come too late for the current…

Anti-viralsAVI-6002GlaxoSmithKlinePharmaceuticalProductionResearchSarepta Therapeutics

Pharmacyclics’ Imbruvica gains EU approval for two blood cancers

17-10-2014

US drugmaker Pharmacyclics has received marketing approval from the European Commission for Imbruvica…

EuropeImbruvicaJohnson & JohnsonOncologyPharmaceuticalPharmacyclicsRegulation

New WikiLeaks revelations on Trans-Pacific Trade Pact Text

17-10-2014

Access to affordable cancer treatments in the USA and 11 other countries would be delayed for years if…

Asia-PacificPatents & Trade marksPharmaceuticalPoliticsUSA

Pharmacyclics and Roche research Imbruvica and Gazyva

Pharmacyclics and Roche research Imbruvica and Gazyva

17-10-2014

USA-based biopharma company Pharmacyclics has entered into a master clinical drug supply agreement with…

GazyvaImbruvicaOncologyPharmaceuticalPharmacyclicsResearchRocheUSA

1 to 25 of 7078 results

Parexel

Parexel

Back to top